Leading supplier of pharmaceutical products to government organizations through tenders from its WHO-GMP approved plant
Developed pellets, granules and taste masking technology platforms to change its focus to differentiated and higher margin products
Ventured into international markets in middle east and North Africa (MENA)
Established ‘Proof-of-Concept’ for oral thin films and nano-technology
Focus on higher margin businesses.
Reduced deemed export and low margin government business.
Upgraded its manufacturing facilities to EU-GMP standards.
Investment in team and processes.
Invested in separate WHO-GMP approved OTF facility and commercialised OTF products
Entered into newer geographies like SEA, Latin America, CIS and Africa and grew Sri Lanka, Bangladesh and MENA
Focused on building a steady pipeline with dossier filings and own product registrations
- ZIM Laboratories Limited got listed on Bombay Stock Exchange, Continued focus in core PFI business through new geographies, new customer relationships and new product pipeline for its business partners
- Growing its niche generic formulations business – through registration, marketing partnerships and continued launch of products in MENA, SE Asia, Latin America and CIS countries (as demonstrated in Sri Lanka)
- Launch of OTF (prescription and OTC products) as an alternate drug delivery platform across RoW / Emerging Markets and Regulated Markets
- Invest in R&D to develop a pipeline of products with focus on developed markets and enhance capacity and flexibility by appropriate capex
ZIM Laboratories got listed on National Stock Exchange (NSE) Nov-2022.